baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Rani Therapeutics Holdings/ US7530181004 /

6/10/2024 9:51:48 PM	Chg. -0.41	Volume	Bid-	Ask-	High	Low
4.10USD	-9.09%	12,176 Turnover: 49,979.25	-Bid Size: -	-Ask Size: -	4.59	4.10

GlobeNewswire 5/14 Rani Therapeutics to Participate in May Investor Conferences

GlobeNewswire 5/9 Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosim...

GlobeNewswire 5/6 Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

GlobeNewswire 3/20 Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Up...

GlobeNewswire 3/15 Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 2/5 Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin ...

GlobeNewswire 12/14/2023 Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incre...

GlobeNewswire 11/8/2023 Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

GlobeNewswire 11/1/2023 Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans t...

GlobeNewswire 10/25/2023 The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repe...

GlobeNewswire 10/19/2023 Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill i...

GlobeNewswire 10/12/2023 Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society f...

GlobeNewswire 9/18/2023 Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT...

GlobeNewswire 9/7/2023 Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

GlobeNewswire 9/6/2023 Rani Therapeutics to Participate in September Investor Conferences

GlobeNewswire 3/24/2022 Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 2...

GlobeNewswire 3/23/2022 Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis

GlobeNewswire 1/7/2022 Rani Therapeutics Appoints Lisa Rometty to Board of Directors

GlobeNewswire 12/11/2021 Annual Changes to the Nasdaq Biotechnology Index

GlobeNewswire 11/16/2021 Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

GlobeNewswire 11/12/2021 Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

GlobeNewswire 11/10/2021 Rani Therapeutics to Participate in a Fireside Chat at the Stifel 2021 Virtual Healthcare Conference

GlobeNewswire 9/23/2021 Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

GlobeNewswire 9/13/2021 Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

GlobeNewswire 9/9/2021 Rani Therapeutics Announces Appointment of Eric Groen as General Counsel

Rani Therapeutics Holdings/ US7530181004 /

If you wish to receive reply to your feedback, please provide your email address.